SCHEMBL18758616

SCHEMBL18758616

COC(=O)c1c(C(F)(F)F)nn2c1N(c1ccc(Cl)cc1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.42
▸ BRD2 P25440 1/20 0.42
▸ BRD3 Q15059 1/20 0.42
▸ MAPT P10636 7/20 0.39
▸ LMNA P02545 5/20 0.39
▸ TP53 P04637 4/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CCR1 P32246 1/20 0.39
▸ POLB P06746 3/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ F10 P00742 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18740013 0.90 CISD2 (0.39) MAPTLMNACCR1POLBALDH1A1
SCHEMBL18740128 0.89 CYP1A2 (0.44) MAPTLMNATP53SMN1; SMN2CCR1
SCHEMBL18758717 0.86 CCR1 (0.39) BRD4BRD2BRD3MAPTLMNA
SCHEMBL18740351 0.83 NOX4 (0.39) MAPTLMNACCR1POLBCYP2C9
SCHEMBL18758724 0.83 BRD4 (0.45) BRD4BRD2BRD3MAPTSMN1; SMN2
SCHEMBL28961686 0.83 BRD4 (0.45) BRD4BRD2BRD3MAPTSMN1; SMN2
SCHEMBL18740218 0.82 MEN1 (0.44) MAPTLMNATP53SMN1; SMN2POLB
SCHEMBL18740275 0.81 LMNA (0.46) MAPTLMNATP53SMN1; SMN2POLB
SCHEMBL18740296 0.78 MEN1 (0.39) MAPTLMNATP53SMN1; SMN2POLB
SCHEMBL18740243 0.77 PTGER4 (0.51) BRD4BRD2BRD3CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
EP-3362454-B1 EP4 ANTAGONISTS EISAI R&D MAN CO LTD (JP) 2021-12-08 — — EP disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
CN-108473497-B EP4 antagonists 卫材R&D 管理有限公司 2021-09-10 — — CN disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
US-20180305362-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-10-25 — — US disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885
US-20180305362-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 BRD4 60/4885BRD2 855/4885BRD3 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback